Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

GlaxoSmithKline Pharmaceuticals Limited

NSE: GLAXOPharmaceuticals

Share price

₹2,534.40

-3.78% close of 8 Oct 2026

Market cap ₹42,831 CrP/E 40.7

Business score

How strong the business is, in one number. The parts behind it are in Pro.

64

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹42,831 Cr

P/E ratio

40.7

P/B ratio

18.9

ROCE

61.4%

ROE

45.6%

Dividend yield

2.2%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹3,106.4052-week low ₹2,103.20

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 5.8% over the past year, and 4.6% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 23.3% to 34.2% over the last four years.

Whether it grew faster than its sector

It grew 4.6% a year against a sector median of 13.1% — 8.5 percentage points slower.

Room to re-rate, or risk of de-rating

At 40.7× earnings it costs 1.7× the market, which pays 23.9× across 2199 companies we can price. Its own industry sits at 78.7×, across 5 companies. It is against its own five-year median of 46.1×, the 32nd percentile of its own range.

Whether growth justifies the valuation

Priced at 2.3 times its growth rate, on earnings growth of 18%.

Profit growthPrice per ₹1 profitPer 1% growth
GlaxoSmithKline Pharmaceuticals Limited — this one18%/yr40.7×₹2.3
Sun Pharmaceutical13%/yr33.4×₹2.6
Divi's Laboratories13%/yr83.3×₹6.4
Torrent Pharmaceuticals22%/yr78.7×₹3.6
Zydus Lifesciences32%/yr23.1×₹0.72
Laurus Labs Limited4%/yr98.6×₹24.7

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 4 of 130 on returns, 103 of 127 on growth, 13 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

A wide advantage: it earns 61.4% on capital, ahead of 97% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹4070 crore of cash from the business, spent ₹1447 crore on plant and equipment, and returned ₹4135 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 12 years, about 92 arrived as cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

8 of 9 checks clear · 89%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Sales up 15% and newly launched medicines now make up 7% of the top line

Announced 3 Aug 2026 · Consolidated · Unaudited

Revenue

₹938 Cr

Revenue vs last year

+16.6%

Revenue vs last quarter

-5.7%

Net profit

₹237 Cr

Profit vs last year

+15.7%

Profit vs last quarter

-14.7%

Net margin

25.3%

EPS

₹14.00

Earnings call transcript · 3 Aug 2026

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹42,831 Cr
Prev close
₹2,534.40
52w High
₹3,121
52w Low
₹2,088
Enterprise value
₹41,577 Cr
Beta
0.6
Price CAGR 1y
-4.0%
Price CAGR 3y
20.0%
Price CAGR 5y
12.0%
Price CAGR 10y
6.0%

Ratios

Return on assets
24.0%
PEG ratio
2.3
P/E ratio
40.7
P/B ratio
18.9
EV / EBITDA
32.8
Industry P/E
38.0
ROCE
61.4%
ROCE 5y average
49.6%
ROE
45.6%
Debt / Equity
0.0
Interest coverage
469.7
Dividend yield
2.2%
ROE 3y average
43.0%
ROE last year
46.0%

Annual P&L

Annual revenue
₹3,822 Cr
Annual profit
₹1,036 Cr
Operating margin
34.0%
Net profit margin
27.1%
EBITDA margin
34.2%
Sales growth 3y
5.5%
Sales growth 5y
5.5%
Profit growth 3y
18.0%
Profit growth 5y
15.0%
EPS
₹61.2
Sales growth TTM
6.0%
Profit growth TTM
11.0%
Dividend payout
93.0%

Quarter P&L

Sales latest quarter
₹938 Cr
Profit latest quarter
₹237 Cr
YoY quarterly sales growth
16.6%
YoY quarterly profit growth
15.6%
OPM latest quarter
31.5%

Balance Sheet

Book Value
₹134
Face Value
₹10.0
Total debt
₹33 Cr
Total cash
₹1,391 Cr
Borrowings
₹33 Cr
Reserves / Equity
12.4

Cash Flow

Operating cash flow
₹903 Cr
Free cash flow
₹849 Cr
FCF yield
2.0%
Net cash flow
₹563 Cr

Shareholding

Promoter holding
75.0%
FII holding
4.8%
DII holding
7.8%
Public holding
12.4%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,781.0033.84,27,3220.902,901.26.015,299.910.520.5
Divi's Lab.9,588.0085.42,54,5310.31902.065.53,080.027.822.0
Torrent Pharma.4,716.2080.41,79,3890.81566.05.84,921.054.915.2
Zydus Lifesci.1,153.0023.61,15,0120.09990.2-35.18,017.022.021.1
Laurus Labs2,052.80101.41,10,9150.10362.1125.52,026.329.117.8
Cipla1,327.2030.01,07,2210.98785.6-39.27,119.32.315.5
Mankind Pharma2,500.0048.41,03,2610.04574.129.64,030.612.913.5
Glaxosmi. Pharma2,634.0042.444,6222.16237.215.7938.416.661.4
Median417.9034.52,2080.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales7629578059308151,0119499748059801,041995938
Expenses618668587673584689658641554644670644643
Material Cost1281158011373
Change in Inventories-727.68672.54-124
Purchases of Stock-in-Trade232233217228379
Employee Cost153138152165159
Other Expenses114151154136156
Operating Profit144289218257231322292333251336371351296
OPM %19302728283231343134363531
Other Income5428-13532363935414436503644
Exceptional items (within Other Income)02.641800
Interest0001000101111
Depreciation16181718161719151617201316
Profit before tax18129965271249344308359279354400373322
Tax %27273028272725272727262626
Net Profit13221846194182252230263205257296278237
EPS in Rs7.81132.7011111514161215171614
Diluted EPS in Rs1215171614

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2015 15mMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales3,3052,8382,9082,8713,1283,2242,9263,2783,2523,4543,7493,8223,955
Expenses2,6722,3602,4892,3632,5272,5672,3272,5162,4472,5452,5702,5122,601
Material Cost436
Change in Inventories4.46
Purchases of Stock-in-Trade910
Employee Cost607
Other Expenses554
Operating Profit6334784205086016575987628049091,1791,3091,354
OPM %19171418192020232526313434
Other Income14912511970131-26291,401103-21149166166
Exceptional items (within Other Income)21
Interest000016422212.733
Depreciation25252738498379686670676667
Profit before tax7565785115406833065252,0938398161,2601,4061,449
Tax %373534353570321927282626
Net Profit476376337351445933581,6956115909281,0361,068
EPS in Rs28222021265.50211003635556163
Diluted EPS in Rs55
Dividend Payout %1111137585767271429089929993

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
3%
5 years
5%
3 years
6%
TTM
6%

Compounded profit growth

10 years
10%
5 years
15%
3 years
18%
TTM
11%

Stock price CAGR

10 years
6%
5 years
12%
3 years
20%
1 year
-4%

Return on equity

10 years
33%
5 years
48%
3 years
43%
Last year
46%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital85858585169169169169169169169169
Reserves1,7442,0991,9221,9731,9701,6511,3092,4941,5721,6081,7822,098
Borrowings322110352016191033
Other Liabilities1,3848699951,8891,7711,3151,6021,9501,5701,7602,1472,023
Minority Interest17
Total Liabilities3,2163,0553,0043,9473,9113,1363,1154,6333,3273,5574,1084,324
Fixed Assets123204258325432758387331330321284281
CWIP1152686059231,003120133020141433
Investments06000003665188131,1181,392
Other Assets2,9772,5772,1402,7002,4772,2572,7153,9072,4582,4082,6922,618
Total Assets3,2163,0553,0043,9473,9113,1363,1154,6333,3273,5574,1084,324

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity3381392344734094905788114845821,290903
Cash from Investing Activity180499301-104-153-57418-4068089-46397
Cash from Financing Activity-497-638-511-307-358-428-696-524-1,543-562-769-737
Net Cash Flow21-02462-1026300-119-25129475563
Free Cash Flow175-69-246391663365362,3714515731,273849

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days111621191411272322232826
Inventory Days91156111147131135159144131144126124
Days Payable749773149109100135156122171186154
Cash Conversion Cycle277560173646501131-4-31-4
Working Capital Days-48267-90-72-38-39-94-57-64-99-91
ROCE %422922263133383736516361

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters757575757575757575757575
FIIs2.502.933.484.024.364.504.524.894.794.634.624.79
DIIs108.647.907.517.347.307.797.717.757.707.687.81
Government0.010.010000000000
Public121314131313131212131312
No. of Shareholders1,15,2681,14,6631,18,9941,18,5151,19,2281,19,6251,21,8851,23,6291,22,9041,22,4601,21,7631,26,087

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year -8.2% (₹2,761.00 → ₹2,534.40)Brick size ₹89.92 (fixed)Bricks 28
₹2,250₹2,750₹3,000₹2,534Nov '25Feb '26May '26Aug '26
Price moved up one brickPrice moved down one brickLast close ₹2,534.40 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

1,22,14,631inr

2026-03-31

volume growth %

3.00pct

2026-06-30

News

News and filings about GlaxoSmithKline Pharmaceuticals Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • Power, fuel and water (Nashik manufacturing)
  • Raw materials and packing materials
  • Traded pharmaceutical goods (finished/specialty medicines imported from GSK group)
  • Vaccines and specialty medicines (imported finished products)

Depends on the price of

  • water

Buys drug ingredients from

  • GlaxoSmithKline Asia Private Limited, India
  • GlaxoSmithKline Biologicals S.A., Belgium
  • GlaxoSmithKline Export Limited, U.K.

Buys from

Sells to

  • Indian Government Institutions / public healthcare · Vaccines and general medicines (institutional/tender supply)
  • PT Glaxo Wellcome Indonesia · Pharmaceutical products / traded goods (intra-group export)

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE159A01016

Plants

  • GSK Nashik Manufacturing Facility

News impact

Big market events that reach GlaxoSmithKline Pharmaceuticals Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

29 May 2026unspecified₹57
30 May 2025unspecified₹42
7 Nov 2024interim₹12
31 May 2024unspecified₹32
30 Jun 2023unspecified₹32
7 Jul 2022unspecified₹30
7 Jul 2022special₹60
19 Jul 2021unspecified₹30

Splits, bonuses & buybacks

  • daily-prices repair: 9 rows from NSE's archive (replace 1, delete 1, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.